Drug intelligence / Profile preview

NPM-159

Development stage: Unknown
Lead developer: Vivani Medical, Inc
Modality: Peptides

Overview

NPM-159 is a synthetic peptide drug candidate under preclinical development by Vivani Medical for the treatment of nonalcoholic steatohepatitis (NASH). The mechanism of action is as an agonist of the glucagon-like peptide 1 receptor (GLP-1R), which is a well-validated target in the metabolic disease space. Peptide activation of GLP-1R is designed to improve insulin secretion, suppress appetite, and reduce hepatic steatosis.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on NPM-159.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPM-159.

Explore the full profile